Buspirone Back to the Future
Buspirone Back to the Future
复制标题
DOI：
10.3928/02793695-20151022-01
复制
发表时间：
2015-11-01
影响因子：
1.2
通讯作者：
Howland, Robert H.
中科院分区：
文献类型：
--
作者：
Howland, Robert H.
丁螺环酮于1968年首次合成，1986年上市，是一种独特的氮杂螺环酮药物。它对治疗广泛性焦虑症有效，但对其他焦虑症无效。丁螺环酮单独或与抗抑郁药一起使用对抑郁症也有效，并可用于治疗不良性影响。丁螺环酮用于物质使用障碍的研究结果令人失望，尽管它可能有助于治疗共存的焦虑，一项对照研究表明对海洛因戒毒有效。丁螺环酮可以被认为是一种治疗选择，用于管理老年痴呆症患者以及儿科患者的易怒、激越和攻击性，尽管需要进行额外的有效性研究。丁螺环酮和褪黑激素可以协同促进神经发生，支持这种组合用于治疗抑郁症和认知障碍的潜在用途。
Buspirone, first synthesized in 1968 and marketed in 1986, is a pharmacologically unique azapirone drug. It is effective for treating generalized anxiety, but not other anxiety disorders. Buspirone also is efficacious for depression, either alone or together with an antidepressant drug, and for treating adverse sexual effects. Studies of buspirone for substance use disorders have had disappointing outcomes, although it may be useful for treating coexisting anxiety and one controlled study suggested efficacy for heroin detoxification. Buspirone may be considered a treatment option for managing irritability, agitation, and aggression in older adult patients with dementia as well as in pediatric patients, although additional effectiveness studies are warranted. Buspirone and melatonin may synergistically promote neurogenesis, supporting the potential use of this combination for treating depression and cognitive impairment.